Value Analysis of Ceftazidime-avibactam in the Treatment of acquired Pneumonia after Kidney Transplantation
Objective To observe the effects of ceftazidime-avibactam on symptom improvement time,lung function,and blood gas analysis indicators in patients with acquired pneumonia after kidney transplantation,and analyze its value in the treatment of acquired pneumonia after kidney transplantation.Methods A total of 70 patients with acquired pneumonia after kidney transplantation admitted to Zhengzhou People's Hospital from May 2019 to July 2020 were selected as the observation targets.They were randomly divided into control group of 35 cases(treated with imipenem and cilastatin sodium injection)and study group of 35 cases(treated with ceftazidime-avibactam)according to the random number table.The difference of therapeutic effect and adverse reaction between groups were compared.Results After treatment,the clinical symptoms of both groups were significantly reduced compared to before treatment,and the clinical symptom scores of the study group were significantly lower than those of the control group,with statistical significance(P＜0.05).The study group had significantly shorter fever duration,disappearance time of dry and wet rales in the lungs,and improvement time of cough and sputum compared to the control group,with statistical significance(P＜0.05).After treatment,the lung function data of both groups showed significant improvement compared to before treatment,and the study group was significantly higher than the control group,with a statistically significant difference(P＜0.05).After treatment,the SaO2,PaO2,and OI of both groups were significantly increased compared to before treatment,while PaCO2 was significantly reduced.The SaO2,PaO2,and OI of the study group were significantly higher than those of the control group,and PaCO2 was significantly lower than those of the control group,with statistical significance(P＜0.05).The treatment effective rate(88.57%)and pathogen clearance rate(80.00%)of the study group were higher than those of the control group(71.43%)and pathogen clearance rate(54.29%),with statistically significant differences(P＜0.05).Conclusion Ceftazidime-avibactam has an improving effect on lung function and blood gas analysis indicators in acquired pneumonia after kidney transplantation,enhancing treatment efficacy.
国家科技期刊平台
NSTL
万方数据
维普
